Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18 to 45~* Absence of pregnancy~* Patients with chronic pelvic pain and / or dysmenorrhea with pain scores ≥ 4 on EVA pain and surgical and histopathological diagnosis of endometriosis in 14 last three months to two years, according to the current classification of the American Society for Reproductive Medicine and Enzian classification.~* Accept participate and sign the consent form and clarified~Exclusion criteria:~* Current wish to get pregnant~* I just want to use the LNG-IUS as treatment~* Contraindication to the use of LNG-IUS: Current pelvic inflammatory disease or appellant; infection of the lower genital tract; infected abortion during the last 3 months; purulent cervicitis; uterine or cervical malignancy; bleeding abnormal uterine undiagnosed; congenital uterine anomalies or acquired conditions associated with increased susceptibility to infections; acute liver disease or liver tumors; hypersensitivity to LNG.~* Contraindications to the use of ENG implants: pregnancy or suspected pregnancy;~* Active venous thromboembolic disorder; presence or history of liver disease serious as liver function values have not returned to normal; progestogen dependent tumors; abnormal bleeding undiagnosed; hypersensitivity to any component of implante.~* Abusive use of alcohol and / or other illicit drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- levonorgestrel & etonogestrel (Type: EXPERIMENTAL): Levonorgestrel releasing intrauterine system~Other names:~Mirena.
- etonogestrel (Type: ACTIVE_COMPARATOR): Etonogestrel implant:~Other name: Implanon Releasing 20μg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).